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ABSTRACT The antinociceptive effect of huperzine A, a novel cholinesterase inhibitor, was investigated
in the mouse hot-plate and abdominal constriction tests. Huperzine A induced a dose-dependent
antinociception (70–110 m g kg–1 i.p.) which was prevented by scopolamine (0.1 mg kg–1 i.p.) and S-(–)-ET
126 (0.01 m g per mouse i.c.v.), but not by naloxone (1 mg kg–1 i.p.), mecamylamine (2 mg kg–1 i.p.), a -
methyl-p-tyrosine (100 mg kg–1 i.p.), or CGP 35348 (100 mg kg–1 i.p.). A dose-dependent inhibition of the
antinociception induced by huperzine A (110 m g kg–1 i.p.) was observed after inactivation of the M1 gene by
an antisense oligodeoxyribonucleotide (aODN). This effect was detected 24 h after the last intracerebro-
ventricular injection of aODN. Time-course experiments revealed that, after the end of the aODN treat-
ment, sensitivity to analgesic drugs progressively appeared, reaching the normal range at 96 h. Huperzine
A, at the maximal effective doses, did not produce any alteration of mice motor coordination, as revealed by
rota-rod experiments. These results indicate that huperzine A is endowed by muscarinic antinociceptive
properties mediated by the activation of central M1 muscarinic receptor subtype.  Drug Dev. Res. 54:19–
26, 2001. © 2001 Wiley-Liss, Inc.
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INTRODUCTION
It is widely accepted that organisms possess endog-
enous systems within the central nervous system that in-
hibit nociceptive transmission. Several reports have
provided evidence for the critical involvement of the cho-
linergic system in such pain inhibitory pathways. The first
observation that the cholinesterase inhibitor physostig-
mine increased the pain threshold in man was made more
than 60 years ago [Pellandra, 1933]. Since then, a vast
literature has appeared describing the antinociceptive ac-
tion of both cholinesterase inhibitors and cholinomimetic
drugs [Hartvig et al., 1989]. Bhargava and Way [1972]
showed that elevation of acetylcholine (ACh) in brain,
produced by cholinesterase inhibitors, enhanced mor-
phine-induced analgesia. In addition, it has been reported
that physostigmine is endowed with antinociceptive prop-
erties in rat cold-water swimming. The enhancement of
pain threshold is prevented by the administration of the
muscarinic antagonists scopolamine and benactyzine
[Romano and Shih, 1983]. Intrathecal and systemic ad-
ministration of acetylcholinesterase (AChE) inhibitors has
been reported to produce antinociception in several ani-
mal species, including mice [Yaksh et al., 1985; Smith et
al., 1989; Naguib and Yaksh, 1994; Ghelardini et al., 2000].
Human studies have confirmed the analgesic ac-
tion of the anticholinesterase agent physostigmine given
intravenously [Scott and Loh, 1984; Pettersson et al.,
1986]. Furthermore, neostigmine has been recently
shown to produce long-lasting postoperative analgesia
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[Klamt et al., 1997] and to enhance opioid analgesia in
human patients [Lauretti et al., 1996; Klamt et al., 1999;
Nelson et al., 1999].
It has been reported that muscarinic analgesia in
mice and rats is mediated by postsynaptic M1 receptors.
M1 selective agonists McN-A-343 and AF-102B are able
to produce a significant enhancement of the pain thresh-
old antagonized by the M1 antagonists dicyclomine and
pirenzepine [Bartolini et al., 1992]. The analgesia induced
by the cholinesterase inhibitors neostigmine and phys-
ostigmine was prevented by M1 antagonists [Bouaziz et
al., 1995) and by anti-M1 ODN treatment [Ghelardini et
al., 2000].
Huperzine A is an alkaloid isolated from a Chinese
club-moss which is a potent and selective inhibitor of
AChE [Tang et al., 1989]. Several pharmacological and
clinical studies showed that huperzine A improves the
mnesic capacity and cognitive functions [Ye et al., 1999].
Huperzine A was also found to be a neuroprotective agent
[Ved et al., 1997]. This molecule which possesses a high
pharmacological potential is under clinical evaluation for
the palliative treatment of Alzheimer’s disease [Skolnick,
1997]. In addition, its use in the pretreatment of poison-
ing by organophosphorous nerve agents could be another
indication [Pilotaz and Masson, 1999].
On the basis of the observation that anticholinesterase
inhibitors showed analgesic activity, the aim of the present
study was to investigate the potential antinociceptive pro-
file of huperzine A and its mechanism of action.
MATERIALS AND METHODS
Animals
Male Swiss albino mice (23–30 g) from Morini (San
Polo d’Enza, Italy) were used. The mice were housed 15
per cage. The cages were placed in the experimental room
24 h before the test for adaptation. The animals were fed
a standard laboratory diet and tap water ad libitum and
kept at 23 –  1° C with a 12-h light/dark cycle, lights on at
7 AM. Animals were used once. All experiments were car-
ried out according to the guidelines of the European
Community Council for experimental animal care.
Antisense Oligonucleotides
Low cell permeability and the high degradation of
natural phosphodiester oligomers are considerable draw-
backs in the application of antisense oligonucleotides
(aODNs), both in vitro and in vivo. To overcome these
drawbacks, phosphorothioate-capped phosphorodiester
oligonucleotides were used. The above-mentioned com-
pounds are a class of ODN derivatives shown to main-
tain more stable and effective concentrations in the brain
when compared with their unmodified counterpart
[Whitesell et al., 1993]. Phosphodiester oligonucleotides
(ODNs) protected by terminal phosphorothioate double
substitution (capped ODNs) against possible exonu-
clease-mediated degradation were purchased from
Genosys (Cambridge, UK) and purified by high-perfor-
mance liquid chromatography (HPLC). The 18-mer
antisense ODN (aODN) 5 ¢ -CAC TGA GGT GTT CAT
TGC-3 ¢  (phosphorothioate residues are underlined)
complementary to the residues 112–129 of the published
mouse M1 cDNA sequence [Shapiro et al., 1988] and the
18-mer fully degenerated ODN (dODN) 5 ¢ -NNN NNN
NNN NNN NNN  NNN-3¢  (where N is G, or C, or A, or
T and phosphorothioate residues are underlined) were
vehiculated intracellularly by an artificial cationic lipid
(DOTAP; Boehringer-Mannheim, Germany) to enhance
both uptake and stability, as described previously [Cap-
accioli et al., 1993; Quattrone et al., 1994]. aODN or dODN
(100–400 m M) were preincubated at 37° C for 30 min with
13 m M DOTAP, sterilized through a 0.2-m m filter, and sup-
plied to mice by intracerebroventricular (i.c.v.) injection
of a 5 m l solution as described in the next section.
GenBank Accession Numbers
The accession number of the cDNA sequence for
the mouse muscarinic receptor subtype reported in this
article (M1) is J04192.
Intracerebroventricular Injection of Oligonucleotides
Mice were randomly assigned to anti-M1 aODN,
dODN, vehicle, saline, or naive group. The antisense and
dODNs were dissolved in a vehicle constituted of DOTAP.
Each group received a single i.c.v. injection on days 1, 4,
and 7, whereas naive animals did not receive any treat-
ment. I.c.v. administration was performed under ether
anesthesia with isotonic saline as solvent, according to the
method described by Haley and McCormick [1957]. Dur-
ing anesthesia mice were grasped firmly by the loose skin
behind the head. A hypodermic needle (0.4 mm external
diameter) attached to a 10 m l syringe was inserted perpen-
dicularly through the skull and no more than 2 mm into
the brain of the mouse, where 5 m l ODNs were then ad-
ministered. The injection site was 1 mm to the right or left
from the midpoint on a line drawn through to the anterior
base of the ears. Injections were performed randomly into
the right or left ventricle. To ascertain that ODNs were
administered exactly into the cerebral ventricle, some mice
(10%) were injected with 5 m l of diluted 1:10 India ink and
their brains were examined macroscopically after section-
ing. The accuracy of the injection technique was evalu-
ated, with 95% of injections being correct.
Hot-Plate Test
The method adopted was described by O’Callaghan
and Holtzman [1975]. Mice were placed inside a stain-
less steel container, which was set thermostatically at 52.5
–  0.1° C in a precision water-bath from KW Mechanical
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Workshop (Siena, Italy). Reaction times(s) were measured
with a stopwatch before and 15, 30, and 45 min after
huperzine A administration. The endpoint used was the
licking of the fore- or hindpaws. Those mice scoring less
than 12 and more than 18 sec in the pretest were re-
jected (30%). To prevent tissue injury, an arbitrary cut-
off time of 45 sec was adopted.
Abdominal Constriction Test
Mice were injected intraperitoneally (i.p.) with a
0.6% solution of acetic acid (10 ml kg–1), according to
Koster et al. [1959]. The number of stretching movements
was counted for 10 min, starting 5 min after acetic acid
injection.
Rota-Rod Test
The apparatus consists of a base platform and a ro-
tating rod of 3 cm diameter with a nonskid surface. The
rod was placed at a height of 15 cm from the base. The
rod, 30 cm in length, was divided into five equal sections
by six disks. Thus, up to five mice were tested simulta-
neously on the apparatus, with a rod-rotation speed of 16
rpm. The integrity of motor coordination was assessed
on the basis of the number of falls from the rod in 30 sec,
according to Vaught et al. [1985]. Performance time was
measured before and 15, 30, and 45 min after i.p. admin-
istration of the investigated compounds.
Reagents and Compounds
The following drugs were used: huperzine A (gift of
Prof. Nha, Medical School, University of Atlanta, Atlanta,
GA), scopolamine hydrobromide, baclofen ( b -p-
chlorophenyl GABA), naloxone hydrochloride, DL- a -
methyl-p-tyrosine methylester hydrochloride ( a -MpT)
(Sigma, St. Louis, MO), morphine hydrochloride (USL
10/D, Firenze, Italy); mecamylamine hydrochloride (RBI,
Natick, MA); CGP 35348 (3-aminopropyl-diethoxy-
methyl-phosphinic acid) (Ciba-Geigy, Summit, NJ); S-
(–)-ET 126 (S-(–)- a -(hydroxymethyl)benzene-acetic acid
1-methyl-4-piperidinyl ester; prepared in the Department
of Pharmaceutical Sciences of Florence, Italy, as described
by Gualtieri et al. [1991]).
Drug concentrations were prepared in such a way
that the necessary dose could be administered in a volume
of 5 m l per mouse by i.c.v. injection and 10 ml kg–1 by i.p.
injection. All drugs were dissolved in saline solution.
Statistical Analysis
All experimental results are given as the means –
SEM. An ANOVA followed by Fisher’s Protected Least
Significant Difference (PLSD) procedure for post-hoc
comparison was used to verify the significance of differ-
ences between two means. Data were analyzed with the
StatView software for the Macintosh (1992).
RESULTS
Antinociceptive Activity of Huperzine A
The cholinesterase inhibitor huperzine A, as shown
in Figure 1, produced a dose-dependent increase in the
pain threshold in the mouse hot-plate test (70–110 m g
kg–1 i.p.). The antinociceptive effect of huperzine A
peaked 15 min after administration and then slowly di-
minished. Huperzine A was also able to produce
antinociception in the mouse acetic acid abdominal con-
striction test. The cholinesterase inhibitor induced an
increase in the pain threshold in a dose-dependent man-
ner starting from the dose of 20 m g kg–1 i.p. (Fig. 2). In
both tests the antinociception induced by huperzine A
was compared with that exhibited by morphine, used as
reference drug (Figs. 2, 3).
In the mouse hot-plate test, the antinociceptive ef-
fect of huperzine A (110 m g kg–1 i.p.) was not antagonized
by naloxone (1 mg kg–1 i.p.), mecamylamine (2 mg kg–1
i.p.), a -MpT (100 mg kg–1 i.p.), or CGP-35348 (100 mg
kg–1 i.p.), administered, respectively, 5, 15, 120, and 5
min before huperzine A (Table 1). Conversely, the
unselective muscarinic antagonists scopolamine (0.1 mg
kg–1 i.p.) and the selective M1 antagonist S-(–)-ET 126
Fig. 1. Antinociceptive effect of huperzine A in comparison with mor-
phine in mouse hot-plate test. Each point represents the mean of 10–22
mice. Vertical lines show SEM. *P < 0.01; ^P < 0.05 in comparison
with saline-treated mice.
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(0.01 m g per mouse i.c.v.), administered 20 min before
test, prevented huperzine A antinociception in the mouse
abdominal constriction (Fig. 2) and hot-plate (Fig. 3) tests.
Scopolamine, at the same concentration, did not prevent
the analgesia induced by morphine (7 mg kg–1 i.p.) and
baclofen (4 mg kg–1 i.p.) (Fig. 3).
Effect of Anti-M1 ODN on Huperzine A
Antinociception
Mice were pretreated with a single i.c.v. injection
of antisense ODN (aODN) to M1 gene, degenerate ODN
(dODN), or vehicle on days 1, 4, and 7. The effect of
aODN pretreatment on huperzine A (110 m g kg–1 i.p.)-
induced antinociception was then evaluated in the mouse
hot-plate test.
aODN, at the dose of 0.3 nmol per i.c.v. injection,
did not significantly affect huperzine A (Fig. 4A) analge-
sia, whereas at the dose of 1.0 and 2.0 nmol per i.c.v.
injection, aODN dose-dependently prevented huperzine
A (Fig. 4B,C), antinociception. This antagonistic effect
was detected 24 h after the last i.c.v. injection.
The regression line which illustrates the dose-de-
pendent reduction of huperzine A, antinociception pro-
duced by increasing concentrations of aODN is shown
in Figure 4D. The percentage of the maximum analgesic
effect was evaluated in correspondence with the maxi-
mum effect of analgesic compounds that occurred 15 min
after huperzine A administration. The hot-plate test was
performed 24 h after the end of the ODN treatments.
A time-course study for aODN antagonistic effect
showed that 48 h after the last i.c.v. injection of ODNs
the antinociception produced by huperzine A was com-
pletely prevented (Fig. 5). At 72 h the aODN effect was
still detectable against huperzine A antinociception,
whereas at 96 h this compound was able to enhance the
pain threshold at the same intensity in aODN-, dODN-,
and vehicle-treated mice, indicating the loss of antago-
nistic activity by the anti-M1 aODN (Fig. 5).
The aODN pretreatment (2.0 nmol per i.c.v. injec-
tion) did not prevent the analgesia induced by morphine
(7 mg kg–1 i.p.) and baclofen (4 mg kg–1 i.p.) 24 h after the
end of ODN administration (data not shown).
The aODN pretreatment (2.0 nmol per i.c.v. injec-
tion) did not reduce the pain threshold in mice showing
a lack of any hyperalgesic effect (Fig. 4). Furthermore,
the pretreatment with the dODN never modified
huperzine A-induced antinociception in comparison with
mice injected with vehicle, as shown in Figure 4.
Effect of Huperzine A on Mouse Behavior
Mice pretreated with huperzine A were evaluated
for motor coordination by use of the rota-rod test (Table
2). The number of falls, evaluated before and 15, 30, and
45 min after the beginning of the rota-rod test, showed the
lack of any impairment in the motor coordination of ani-
mals pretreated with huperzine A at the dose of 110 m g
kg–1 i.p. (Table 2). The number of falls by control animals
progressively decreased at every measurement, since the
mice learned how to balance on the rotating rod.
Conversely, a double dose of huperzine A produced
an increase in the number of falls from the rotating rod,
indicating the induction of motor side effects, as well as
diphenhydramine 30 mg kg–1 i.p. (sedative reference
drug) and scopolamine 5 mg kg–1 i.p. (amnesic reference
drug) (Table 2).
DISCUSSION
Huperzine A was able to induce antinociception in
mice that was elicited regardless of which noxious stimu-
Fig. 2. Antagonism of scopolamine (0.1 mg kg–1 i.p.) and S-(–)-ET 126
(0.01 m g per mouse i.c.v.) on the antinociceptive effect of huperzine A in
mouse abdominal constrictions test. The nociceptive responses were re-
corded 15 and 30 min after huperzine A and morphine administration,
respectively. Scopolamine and S-(–)-ET 126 were injected 10 min before
huperzine A. The doses of huperzine A and morphine expressed as m g
kg–1 i.p. are inside the columns. Vertical lines show SEM. *P < 0.01 in
comparison with saline controls. ° P < 0.01 in comparison with scopola-
mine/S-(–)-ET 126-treated mice. Each column represents the mean of at
least 10 mice.
Fig. 3. Effect of scopolamine (i.p.) and S-(–)-ET 126 (i.c.v.) on huperzine
A-, morphine-, and baclofen-induced antinociception in mouse hot-plate
test. Scopolamine and S-(–)-ET 126 were administered 10 min before the
other drugs. Nociceptive response was recorded 15 min after huperzine
A (110 m g kg–1 i.p.) and 30 min after morphine (7 mg kg–1 i.p.) and baclofen
(4 mg kg–1 i.p.) injection. Number of mice ranged between 8–18. Verti-
cal lines show SEM. *P < 0.01 vs. saline-treated mice. ° P < 0.01 vs.
huperzine A-treated mice.
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lus was used: thermal (hot-plate) or chemical (abdominal
constriction test). Huperzine A antinociception was ob-
tained without producing any visible modification of ani-
mal gross behavior. Moreover, huperzine A-treated mice
showed a complete integrity of motor coordination on
the rota-rod test. Since animals learned how to balance
on the rotating rod, the number of falls by control ani-
mals progressively decreased at every measurement. The
increase or the lack of variation of the number of falls
represents an index of the induction of motor incoordi-
nation that could lead to a misinterpretation of the re-
sults obtained in the hot-plate test. By contrast, a
reduction of the number of falls after treatment indicates
unimpaired mouse motor coordination. Mice, even if still
sensitive to the thermal stimulus used in the hot-plate
test, may have no reaction to pain (licking of paws) be-
cause of their impaired motility.
Huperzine A antinociception was found to be de-
pendent on cholinergic activation since it was prevented
by the nonselective muscarinic antagonist scopolamine
at concentrations unable to prevent analgesia induced
by nonmuscarinic drugs such as morphine or baclofen
administered at equiactive doses. The involvement of the
M1 receptor subtype in huperzine A antinociception was
postulated by the prevention exerted by the M1 selective
antagonist S-(–)-ET 126 at a dose able to block the M1-
induced analgesia [Ghelardini et al., 1996).
Furthermore, it has been demonstrated that cho-
linergic antinociception in mice is mediated by M1 re-
ceptor stimulation. The use of pharmacological agonists
and antagonists evidenced the involvement of M1 recep-
tors in muscarinic analgesia [Bartolini et al., 1992;
Iwamoto and Marion, 1993; Ghelardini et al., 1996;
Naguib and Yaksh, 1997]. The antinociception induced
by huperzine A is prevented, in a dose-related manner,
by i.c.v. administration of an antisense to the M1 gene
coding for the mouse M1 receptor, further confirming that
the enhancement of the pain threshold produced by this
compound is of the cholinergic type. These results are in
agreement with the prevention of the antinociception
induced by physostigmine, a cholinesterase inhibitor,
exhibited by anti-M1 ODN treatment [Ghelardini et al.,
2000]. The specificity of the anti-M1 ODN employed was
demonstrated by experiments that evidenced a selective
reduction at both M1 mRNA and protein levels in mouse
brain [Ghelardini et al., 1999, 2000].
The prevention by i.c.v. injection of the aODN also
indicates that the antinociception induced by huperzine
is centrally mediated.
The aODN treatment induces a transient preven-
tion of muscarinic antinociception since the inhibition of
huperzine A antinociception disappeared 96 h after the
last i.c.v. injection of the aODN. This return to normal
sensitivity to analgesic treatments could imply both the
total reversal of aODN-induced specific inhibition of M1
gene expression and a lack of damage or toxicity associ-
ated with aODN treatment.
In these experimental conditions, anti-M1 aODN
did not modified the licking latency values of mice in
comparison with control groups (dODN, saline, naive),
excluding that the prevention of huperzine A antinoci-
ception is due to a hyperalgesic effect of the treatment
used [Ghelardini et al., 2000]. Furthermore, the
antinociception induced by activation of other neurotrans-
mitter systems able to enhance the pain threshold, such
as opioid and GABAergic, were not modified by anti-M1
aODN treatment [Ghelardini et al., 2000]. These data
indicate not only the specificity of the aODN treatment,
but also lead us to exclude a correlation between these
two antinociceptive systems and muscarinic analgesia.
In comparison with the saline group, dODN and
vehicle treatments did not modify the enhancement of
TABLE 1. Lack of Effect of Naloxone, Mecamylamine, a -Methyl-p-tyrosine (a -MpT), and CGP-35348 on Antinociception Induced by
Huperzine A (110 m g kg–1 ip) in the Mouse Hot-Plate Test
Licking latency(s)
After treatment
Pretreatment Treatment Before pretreatment 15 min 30 min 45 min
Saline Saline 13.6 ± 0.7 14.4 ± 1.0 13.9 ± 0.9 14.3 ± 0.8
Huperzine A 14.3 ± 0.9 33.1 ± 2.2* 26.2 ± 1.9* 19.0 ± 2.3
Naloxone Saline 13.5 ± 0.8 14.0 ± 1.5 13.9 ± 1.6 14.3 ± 1.7
1 mg kg–1 ip Huperzine A 14.4 ± 0.7 31.5 ± 2.6* 24.6 ± 2.0* 18.7 ± 1.9
Mecamylamine Saline 14.4 ± 0.9 15.2 ± 1.7 16.3 ± 1.3 14.4 ± 1.2
2 mg kg–1 ip Huperzine A 13.7 ± 1.0 36.7 ± 2.0* 24.5 ± 1.7* 18.4 ± 1.5
a -MpT Saline 14.4 ± 0.9 13.8 ± 1.5 15.5 ± 1.3 15.4 ± 1.2
100 mg kg–1 ip Huperzine A 14.4 ± 1.1 34.0 ± 2.1* 25.9 ± 1.5* 17.3 ± 1.5*
CGP 35348 Saline 13.5 ± 0.7 11.4 ± 1.3** 12.5 ± 2.0 12.7 ± 1.5
100 mg kg–1 ip Huperzine A 14.5 ± 1.5 30.3 ± 2.2* 23.6 ± 2.6* 17.9 ± 1.7
Each value is the mean of 8–12 mice. *P < 0.01; **P < 0.05 in comparison with saline. Naloxone, mecamylamine, a -MpT, and CGP-35348 were
administered 15 min, 5 min, 2h, and 5 min before huperzine A, respectively.
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the pain threshold produced huperzine A, ruling out the
possibility that the antagonism exerted by aODN could
be caused by sequence-independent effects on cerebral
structures. This claim is supported by results obtained
from the quantitative RT-PCR analysis of ODN effects
on M1 gene expression. Quantitative results of M1 mRNA
brain levels following aODN treatment confirmed that
phenotypic effects of anti-M1 aODN on pain modulation
were actually due to the specific inhibition of M1 gene
expression, since dODN did not modify M1 mRNA brain
levels [Ghelardini et al., 1999].
Considering the similarity between the structures
of the muscarinic receptors, a specific anti-M1 aODN was
employed in order to selectively inhibit the expression
of this receptor subtype without interfering with the other
subtypes. The sequence encompassing the translation
start sites of mRNAs, which is considered particularly
prone to aODN action [Goodchild, 1989; Stein and
Cheng, 1993], was compared among the murine known
muscarinic receptors gene family in order to design a
specific antimouse M1 aODN with a very low sequence
homology even with the nearest other members of the
muscarinic receptor family. A homology search in the
GenBank database confirmed the absolute specificity of
the employed aODN. Furthermore, considering the de-
Fig. 4. Prevention of huperzine A (110 m g kg–1 i.p.)-induced
antinociception by pretreatment with an antisense ODN (aODN) to M1
gene in the mouse hot-plate test (A,B,C) and effect of increasing concen-
trations of aODN to M1 gene on huperzine A (110 m g kg–1 i.p.)-induced
antinociception in the same test (D). Mice were i.c.v. injected with ve-
hicle, aODN, or degenerated ODN (dODN) at the dose of 0.3 (A), 1.0
(B), or 2.0 nmol (C) per single i.c.v. injection on days 1, 4, and 7. The hot-
plate test was performed 24 h after the last i.c.v. injection. The evalua-
tion of the analgesic effect was carried out 15 min after huperzine A
administration. Vertical lines give SEM. Each point represents the mean
of 10–14 mice. *P < 0.01 in comparison with dODN +huperzine A-
treated mice.
Fig. 5. Effect of antisense ODN (aODN) to MI gene on huperzine A
(110 m g kg–1 i.p.)-induced antinociception 48, 72, and 96 h after the end
of the aODN treatment. Mice were i.c.v. injected with vehicle, aODN,
or degenerated ODN (dODN) at a dose of 2.0 nmol per single i.c.v.
injection on days 1, 4, and 7. Modification of pain threshold was evalu-
ated by using the mouse hot-plate test. The licking latency was detected
15 min after huperzine A administration. Vertical lines give SEM. Each
column represents the mean of 10–14 mice. ^P < 0.05; *P < 0.01 in
comparison with vehicle-huperzine A-treated mice.
TABLE 2. Effect of Huperzine in the Mouse Rota-Rod Test
Number of falls in 30 s
Before After treatment
Treatment Dose ip pretreatment 15 min 30 min 45 min
Saline 10 ml kg–1 3.3 ± 0.5 2.2 ± 0.4 1.5 ± 0.2 0.8 ± 0.2
Huperzine A 110 m g kg–1 3.5 ± 0.4 1.8 ± 0.5 1.3 ± 0.2 1.0 ± 0.3
Huperzine A 220 m g kg–1 3.4 ± 0.3 3.8 ± 0.4* 2.5 ± 0.4* 1.2 ± 0.3
Each value represents the mean of 10–12 mice. *P < 0.01 in comparison with saline-treated mice.
HUPERZINE A ANALGESIA 25
scribed sequence-independent, nonantisense effects of
ODNs [Storey et al., 1991; Gao et al., 1992; Blagosklonny
and Neckers, 1994; Schick et al., 1995], a fully degener-
ated phosphorothioate capped phosphodiester ODN
(dODN) was used as the most suitable control for these
potentially confusing effects. The dODN used is a col-
lection of about 3 ·  1014 different molecular species. At
concentrations achieved in the nanomolar to micromo-
lar range in in vitro antisense experiments, every spe-
cies, i.e., every ODN of defined sequence, was present
at the site of action at a concentration less than 10–18 M,
which is totally insufficient to achieve any antisense, or
generally sequence-dependent, cellular effect. Therefore,
if ODN i.c.v. administration per se had achieved any bio-
logical response, this would have been present in ODN-
treated controls.
Other neurotransmitter systems are not involved in
Huperzine A antinociception since the opioid antagonist
naloxone, the GABAB antagonist CGP-35348, the cathecol-
amine synthesis inhibitor a -methyl-p-tyrosyne, and the
nicotinic antagonist mecamylamine were all unable to pre-
vent the effect of huperzine A. The doses and administra-
tion schedules of the above-mentioned drugs were ideal
for preventing antinociceptions induced, respectively, by
morphine [Ghelardini et al., 1992], the GABAB agonist
baclofen [Malcangio et al., 1991], nicotine [Ghelardini et
al., 1997], and amphetamine [Bartolini et al., 1987].
In summary, our results have shown that huperzine
A is able to produce dose-dependent antinociception in
mice, without impairing motor coordination, by potenti-
ating endogenous cholinergic activity. These data sug-
gest a potential employment of huperzine A, as well as
other cholinesterase inhibitors, as analgesic for the relief
of painful human conditions.
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